Day: March 13, 2025

Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States

Written by Customer Service on March 13, 2025. Posted in Public Companies.

NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that pricing information for Ryoncil® is now available in all four major drug pricing compendia in the United States. These pricing compendia provide the official source for all information required to order product, including product manufacturing details, National Drug Codes (NDC) for kit purchase, and kit pricing. The pricing compendia listing followed approval and publication by the U.S. Food and Drug Administration (FDA) of the revised Ryoncil® label, which includes revisions to Section 16 (How Supplied / Storage and Handling) of the product prescribing information. The revisions included acceptance of eight new Ryoncil® kits, each with its own NDC,...

Mount Logan Capital Inc. Announces Fourth Quarter and Fiscal 2024 Financial Results

Written by Customer Service on March 13, 2025. Posted in Earnings Releases And Operating Results.

Generated $15.3 million of insurance segment Spread Related Earnings (“SRE”) for the year ended December 31, 2024, a significant increase over the prior year period Asset management segment generated $7.5 million in Fee Related Earnings (“FRE”) for the year ended December 31, 2024, a 36% increase over the prior year, and within our previously stated 2024 FRE guidance range During the quarter, the Company completed an amendment to its existing corporate credit facility, which included an upsize to support key business initiatives and introduced a pricing step-down mechanism During January 2025, the Company announced it entered into a definitive agreement to combine with 180 Degree Capital Corp. (Nasdaq: TURN) in an all-stock transaction. The surviving entity is expected to operate as Mount Logan Capital Inc. (“New Mount Logan”)...

Tree Island Steel Announces Full Year 2024 Results

Written by Customer Service on March 13, 2025. Posted in Earnings Releases And Operating Results.

VANCOUVER, British Columbia, March 13, 2025 (GLOBE NEWSWIRE) — Tree Island Steel (”Tree Island” or the ”Company”) (TSX: TSL) announced today its financial results for the year ended December 31, 2024. For the three-month period ended December 31, 2024, revenues, net of freight and distribution, decreased by $2.5 million to $44.8 million, from $47.3 million in the same period in 2023. The largest drivers for the decreased earnings are the lower average selling prices and the narrowing of margins between selling prices and raw material costs. This was due to competitive pricing pressures across our market segments especially in the residential and industrial segments and led by aggressive import pricing. Gross profit for the fourth quarter decreased to $0.3 million, from $3.4 million in the same period in...

Melcor Developments announces results for 2024, declares $0.11 per share dividend

Written by Customer Service on March 13, 2025. Posted in Earnings Releases And Operating Results.

EDMONTON, Alberta, March 13, 2025 (GLOBE NEWSWIRE) — Melcor Developments Ltd. (TSX: MRD), an Alberta-based real estate development and asset management company, today reported results for the fourth quarter and year ended December 31, 2024. The annual Management Discussion & Analysis (MD&A) and Condensed Interim Financial Statements are available on our website (www.melcor.ca) under Investors, or on SEDAR+ (www.sedarplus.ca). Timothy Melton, Melcor’s Executive Chair and Chief Executive Officer, commented: “We are pleased to present Melcor’s annual results for 2024. Our Canadian Land division benefited from sustained migration into Alberta, fueling steady demand for residential shelter. Strong sales in our Edmonton and Calgary regions contributed to a very good year, with revenues up 12.6% and earnings up 10.8%...

Blue Moon Announces Resumption of Trading, Graduation to Tier 1 on the TSX Venture Exchange and Completion of Share Consolidation Following Transformational Acquisitions

Written by Customer Service on March 13, 2025. Posted in Mergers And Acquisitions.

TORONTO, March 13, 2025 (GLOBE NEWSWIRE) — Blue Moon Metals Inc. (“Blue Moon” or the “Company”) (TSXV: MOON) is pleased to announce that its common shares (the “Blue Moon Shares”) will resume trading on the TSX Venture Exchange (“TSXV”) at the market open on Friday, March 14, 2025. Upon resumption of trading, the graduation of the Company from Tier 2 to Tier 1 issuer status on the TSXV, and the consolidation of the Blue Moon Shares, previously announced on March 3, 2025 and March 10, 2025, respectively, will be effected (the “Consolidation”). Trading of the Blue Moon Shares was halted on November 27, 2024 in connection with the announcement of the acquisitions of Nussir ASA and Nye Sulitjelma Gruver AS, which closed on February 26, 2025. The Company also announced on March 10, 2025, that it acquired all the shares in Repparfjord...

Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update

Written by Customer Service on March 13, 2025. Posted in Earnings Releases And Operating Results.

○ UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) granted by FDA and ODD granted by the European Commission to UCART22 for the treatment of ALL. ○ UCART20x22 Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) ongoing with readout expected in late 2025. ○ AstraZeneca partnership: R&D activities ongoing on three programs – one allogeneic CAR T for hematological malignancies, one allogeneic CAR T for solid tumors, and one in vivo gene therapy for a genetic disorder. ○ Cash position of $264 million as of December 31, 20241 provides runway into mid-2027. ○ Conference call March 14, 2025 at 8:00 am ET / 1:00 pm CET. NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) — Cellectis (the “Company”)...

Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results

Written by Customer Service on March 13, 2025. Posted in Earnings Releases And Operating Results.

The planned merger with Cyclo Therapeutics is anticipated to close in Q3 pending shareholder approvals Post-merger the Company intends to focus its efforts on Cyclo’s lead clinical program Trappsol® Cyclo™ NEWARK, N.J., March 13, 2025 (GLOBE NEWSWIRE) — Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the second quarter and first six months of fiscal year 2025 ended January 31, 2025. “We look forward to the upcoming shareholder vote on our pending merger with Cyclo Therapeutics (Nasdaq: CYTH) later this month and anticipate closing promptly post shareholder approvals. Upon closing, the Company’s strategic focus will be on its lead clinical asset, Trappsol® Cyclo™,” said Bill Conkling, CEO of Rafael Holdings. Bill added, “We are encouraged by the preliminary results presented at the 21st...

Nokia has published its Nokia in 2024 Annual Report and filed its Annual Report on Form 20-F for 2024

Written by Customer Service on March 13, 2025. Posted in Public Companies.

Nokia CorporationStock Exchange Release13 March 2025 at 23:30 EET Nokia has published its Nokia in 2024 Annual Report and filed its Annual Report on Form 20-F for 2024 Espoo, Finland – Nokia has today published its Nokia in 2024 Annual Report, which includes audited financial statements, the annual review by the Board of Directors, including the Sustainability Statement, Nokia’s corporate governance statement and the Remuneration Report for the governing bodies for 2024. Additionally, Nokia has filed its Annual Report on Form 20-F for 2024 with the U.S. Securities and Exchange Commission. The Nokia in 2024 Annual Report and the Annual Report on Form 20-F will be available in PDF format at www.nokia.com/financials. The corporate governance statement will be available also at www.nokia.com/about-us/company/leadership-and-governance and...

BioSyent Releases Financial Results for Fourth Quarter and Full Year 2024

Written by Customer Service on March 13, 2025. Posted in Public Companies.

MISSISSAUGA, Ontario, March 13, 2025 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2024. Key highlights include:(CAD) Q4 2024 % Change vs. Q4 2023 FY 2024 % Change vs. FY 2023 Canadian Pharma Sales 8,546,451 +7 % 32,931,149 +11 % International Pharma Sales 176,734 +223 % 929,975 -11 %Legacy Business Sales 73,499 -68 % 1,169,773 +18 %Total Company Sales 8,796,684 +6 % 35,030,897 +11 %EBITDA1 2,241,112 +36 % 9,343,012 +18 %Net Income After Taxes (NIAT) 1,613,194 +11 % 7,270,104 +13 %Fully Diluted EPS 0.14 +17 % 0.62 +16 % Return on Equity for FY 2024 was 21% as compared to 19% for FY 2023 During FY 2024, repurchased for cancellation a total of 492,300...

Atlanticus Reports Fourth Quarter and Full Year 2024 Financial Results

Written by Customer Service on March 13, 2025. Posted in Earnings Releases And Operating Results.

Fourth Quarter 2024 net margin growth of 28.0% over prior year, with 3.7 million accounts served (1) ATLANTA, March 13, 2025 (GLOBE NEWSWIRE) — Atlanticus Holdings Corporation (NASDAQ: ATLC) (Atlanticus, the Company, we, our or us), a financial technology company that enables its bank, retail and healthcare partners to offer more inclusive financial services to millions of everyday Americans, today announced its financial results for the fourth quarter and full year ended December 31, 2024. An accompanying earnings presentation is available in the Investors section of the Company’s website at www.atlanticus.com or by clicking here. Financial and Operating Highlights Fourth Quarter 2024 Highlights (all comparisons to the Fourth Quarter 2023)Managed receivables2 increased 13.0% to $2.7 billion Total operating revenue and other...

Day: March 13, 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals